ESMO E-Learning: Management of Cancer Associated Thrombosis

Author
Nikolaos Tsoukalas

Provided by
ESMO

ACCESS VALID ONLY FOR ESMO MEMBERS Become a member now

Thrombosis in cancer patients is a common, costly and potentially fatal complication. Patients at highest risk are those with advanced disease receiving systemic chemotherapy and having other additional risk factors.

This E-Learning module provides answers to questions such as why thrombosis occurs in patients with cancer, what is the influence on patient’s prognosis, what is the optimal management, should the patient be managed differently in case of an incidental finding, and could such events be prevented?



Learning objectives
■ To provide in depth update on cancer associated thrombosis
■ To determine which patients are at high risk for cancer associated thrombosis and need thromboprophylaxis
■ To provide recommendations for the management of cancer associated thrombosis

 

Among all cases of venous thromboembolism (VTE), about 20% occur in cancer patients. Furthermore, among all cancer patients, 20% will havesymptomatic VTE.

Compared to patients without cancer, in patients with cancer there is a higher risk of first and recurrent VTE, higher risk of bleeding on anticoagulants, higher risk of dying, with VTE being the second leading cause of death in cancer patients.
Overall, the incidence of cancer associated thrombosis is increasing. Of every seven patients with cancer who die while hospitalised, one will die of pulmonary embolism (PE), 30%-50% will develop post-thrombotic syndrome and 10% severe, while 5% will develop pulmonary hypertension 2 years after symptomatic PE.

Unprovoked VTE may be the earliest sign of cancer. Up to 10% of patients will be diagnosed with cancer in the year after. More than 60% of occult cancers are diagnosed shortly after the diagnosis of unprovoked VTE.
The incidence rate of cancer diagnosis returns to the rate in the general population after one year.
The pathogenesis of a pro-thrombotic state in cancer involves production of procoagulants by tumour cells, suppression of fibrinolytic activity and platelet activation.
In this E-Learning module the author provides a firm evidence of the close link between malignant transformation, tumour Angiogenesis, metastasis and thrombosis.

This CME e-learning granted with official credits from the Educational Portal for oncologist provided by ESMO (Oncology//pro)

Facebook Twitter Google+

Cursos vigentes